On December 11, 2015, the FDA granted accelerated approval to alectinib (ALECENSA®; Genentech, Inc.) for the treatment of patients with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This approval was based on two single-arm trials including 225 patients treated with alectinib 600 mg orally twice daily. The objective response rates (ORR) by independent review committee in these studies were 38% (95% CI, 36-52) and 44% (95% CI 36-53); the median durations of response (DOR) were 7.5 months and 11.2 months. In a pooled analysis of 51 patients with measurable disease in the central nervous system (CNS) at baseline, the CNS ORR was 61% (95% CI 46-74); the CNS DOR was 9.1 months. The primary safety analysis population included 253 patients. The most common adverse reactions were fatigue (41%), constipation (34%), edema (30%), and myalgia (29%). The most common laboratory abnormalities were anemia (56%), increased aspartate aminotransferase (51%), increased alkaline phosphatase (47%), increased creatine phosphokinase (43%), hyperbilirubinemia (39%), hyperglycemia (36%), increased alanine aminotransferase (34%), and hypocalcemia (32%). Dose reductions due to adverse reactions occurred in 12% of patients, while 27% of patients had alectinib dosing interrupted for adverse reactions. Permanent discontinuation of alectinib due to adverse reactions occurred in only 6% of patients. With the clinically meaningful ORR and DOR and the safety profile observed in these trials, alectinib was determined to have a favorable benefit-risk profile for the treatment of the indicated population.
- Received May 20, 2016.
- Revision received June 22, 2016.
- Accepted June 25, 2016.
- Copyright ©2016, American Association for Cancer Research.